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PhosphorylationWe have previously shown that the V-ATPase a2-subunit isoform interacts speciﬁcally, and in an intra-
endosomal acidiﬁcation-dependent manner, with the Arf-GEF ARNO. In the present study, we examined the
molecular mechanism of this interaction using synthetic peptides and puriﬁed recombinant proteins
in protein-association assays. In these experiments, we revealed the involvement of multiple sites on the
N-terminus of the V-ATPase a2-subunit (a2N) in the association with ARNO. While six a2N-derived
peptides interact with wild-type ARNO, only two of them (named a2N-01 and a2N-03) bind to its catalytic
Sec7-domain. However, of these, only the a2N-01 peptide (MGSLFRSESMCLAQLFL) showed speciﬁcity
towards the Sec7-domain compared to other domains of the ARNO protein. Surface plasmon resonance
kinetic analysis revealed a very strong binding afﬁnity between this a2N-01 peptide and the Sec7-domain of
ARNO, with dissociation constant KD=3.44×10−7 M, similar to the KD=3.13×10−7 M binding afﬁnity
between wild-type a2N and the full-length ARNO protein. In further pull-down experiments, we also
revealed the involvement of multiple sites on ARNO itself in the association with a2N. However, while its
catalytic Sec7-domain has the strongest interaction, the PH-, and PB-domains show much weaker binding to
a2N. Interestingly, an interaction of the a2N to a peptide corresponding to ARNO's PB-domain was abolished
by phosphorylation of ARNO residue Ser392. The 3D-structures of the non-phosphorylated and
phosphorylated peptides were resolved by NMR spectroscopy, and we have identiﬁed rearrangements
resulting from Ser392 phosphorylation. Homology modeling suggests that these alterations may modulate the
access of the a2N to its interaction pocket on ARNO that is formed by the Sec7 and PB-domains. Overall, our
data indicate that the interaction between the a2-subunit of V-ATPase and ARNO is a complex process
involving various binding sites on both proteins. Importantly, the binding afﬁnity between the a2-subunit
and ARNO is in the same range as those previously reported for the intramolecular association of subunits
within V-ATPase complex itself, indicating an important cell biological role for the interaction between the
V-ATPase and small GTPase regulatory proteins.a2N, N-terminal cytosolic tail
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Vesicular trafﬁcking within both endocytotic and exocytotic
pathways is an essential cellular process for the function of eukaryotic
cells. In particular, endocytosis is widely used by mammalian cells to
internalize an enormous variety of macromolecules such as proteins,
nutrients, toxins, DNA, RNA as well as microorganisms including
viruses and bacteria. The proper function of both pathways requires
the acidiﬁcation of the lumen of their constituent organelles, which is
driven by the vacuolar-type H+-ATPase (V-ATPase). While the role of
the V-ATPase in acidifying intracellular compartments and extracel-
lular spaces has been long established, we recently uncovered a novel
function of the V-ATPase as an endosomal pH-sensing receptor that
interacts with and recruits Arf-family small GTPases and their
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strated that these cell biological events take place on early endosomes
and are crucial for regulation of the endosomal/lysosomal protein
degradative pathway. Based on these ﬁndings, we hypothesized that
cross-talk between the V-ATPase and Arf small GTPasesmay extend to
acidic organelles in general.
The V-ATPase is a multimeric complex that functions as a proton
pumping nano-motor [3]. Its cytoplasmic V1-sector is involved in
ATP hydrolysis and is composed of eight different subunits arranged
in the following stoichiometry (A3:B3:C1:D1:E3:F1:G3:H1) [4–6].
The transmembrane VO-sector is composed of six different subunits
(a1:c4:c′1:c″1:d1:e1) and is responsible for proton translocation across
the lipid bilayer. V-ATPase structure as well as its cell biological
functions and biochemical regulation have been previously reviewed
in detail [7–12]. The transmembrane a-subunit of the V-ATPase is a
∼100 kDa protein consisting of two dissimilar parts: i) an N-terminal
hydrophilic cytosolic tail and ii) a C-terminal hydrophobic part with
eight putative transmembrane helices [2,13]. Four a-subunit isoforms
(a1, a2, a3 and a4) are found in mammals [9,14–17]. These subunits
are responsible for proper assembly of the V-ATPase and for its
differential targeting to a variety of intracellular organelles and to the
plasma membrane of some specialized cells [3]. Cross-linking, two-
hybrid screening and co-immunoprecipitation experiments showed
that the a-subunit isoforms interact with A-, E-, H-, C-, and G-subunits
of the V1 sector [18–22]. Moreover, increasing experimental evidence
indicates that the cytosolic tails of a-subunit isoforms also interact with
an enzyme of the glycolytic pathway, aldolase B [23–26], which is
involved in glucose-dependent reversible assembly/disassembly of the
VO and V1 sectors, an important regulatory mechanism of V-ATPase
function. Furthermore, another enzyme of the glycolytic pathway,
phosphofrucktokinase-1, directly interacts with the a4-isoform and is
involved in regulation of the function of human V-ATPase [27,28].
ADP-ribosylation factors (Arf) belong to the Ras-superfamily of
small GTPases. These proteins function as molecular switches and
regulate a variety of cell biological events within both endocytotic and
exocytotic trafﬁcking pathways [29–31]. The Arf-family consists of six
members that are categorized into three classes: class I (Arf1, Arf2,
Arf3), class II (Arf4, Arf5) and class III, which is represented by Arf6.
The activation of Arfs (“on”-state in the GTP-bound form) is driven by
guanine nucleotide exchange factors (GEFs), while their deactivation
(“off”-state in the GDP-bound form) is catalyzed by GTPase-activating
proteins (GAPs). Recently, it has been shown that the cytohesin-family
of Arf-GEFs, like Arfs themselves, cycle between inactive and active
conformations, resulting in evenmore tight regulation of Arf activation
[32]. Since GDP/GTP-exchange is coupled to high-afﬁnity membrane
binding of Arfs, Arf-GEFs are also responsible for recruiting Arfs to
speciﬁc membrane domains and are, thus, capable of regulating Arf
activity in a spatial manner. Although several Arf-speciﬁc GEFs and
GAPs were shown to interact with more than one Arf-family member
in vitro, more recent data indicate that each Arf-family member is
regulated by distinct GEFs and GAPs in vivo. All known Arf-GEFs
contain a highly conserved Sec7 catalytic domain, which is responsible
for GEF activity and is related to the prototype yeast protein Sec7p. To
date ﬁfteen Sec7 family members have been identiﬁed in the human
genome [33]. ARNO (also known as, cytohesin-2) is a member of the
cytohesin subfamily of Arf-GEFs, which includes another three
members: cytohesin-1, cytohesin-3 (also called ARNO3 or GRP1) and
cytohesin-4 [33]. Human cytohesins exhibit at least 80% similarity in a
pairwise comparison of their amino acid sequences and share a
common domain organization. Their structure is divided into the
following four regions: i) an N-terminal coiled-coil (CC) domain; ii) a
central Sec7-domain; iii) a pleckstrin homology (PH) domain; and
iv) a C-terminal polybasic (PB) domain. In ARNO, the PB-domain is
phosphorylated at serine392 (Ser392) by protein kinase C (PKC),which
regulates Arf-GEF activity [34]. Recently, a high-resolution crystal
structure of GRP1 (lacking the CC-domain) revealed the regulatoryimportance of a structure connecting the Sec7 and PH-domains
(Sec7-PH-linker) which, together with the PB-domain, is involved in
cytohesin autoinhibition [32].
Previously we identiﬁed the V-ATPase as an endosomal pH-sensor
that scaffolds the cytosolic Arf-GEF ARNO and Arf6 [1,2]. In particular,
we demonstrated that the transmembrane a2-subunit isoform of the
V-ATPase directly interacts with ARNO in an acidiﬁcation-dependent
manner. This biochemical event is essential for vesicular trafﬁcking
between early and late endosomes of the endosomal/lysosomal
protein degradative pathway. However, the molecular details of the
a2-subunit/ARNO interaction and the cell biological signiﬁcance
of this rendezvous in regulating the V-ATPase/ARNO/Arf6 complex
remain unknown. In this study we address these questions and have
uncovered an elaborate, multisite interaction between the V-ATPase
a2-subunit isoform and ARNO, which could be involved in the
regulation of enzymatic activities within this complex.
2. Materials and methods
2.1. Reagents and antibodies
If not otherwise speciﬁed, all reagents were from Sigma (St. Louis,
MO). NU-PAGE gels and buffers were from Invitrogen (Carlsbad, CA).
Criterion gels were from Bio-Rad (Hercules, CA). Protease inhibitor
tablets Complete EDTA-free were from Roche (Indianapolis, IN).
Western Lightning™ Plus chemiluminescence reagent was from
PerkinElmer (Boston, MA). Streptavidin, immobilized on Agarose
CL-4B was from Fluka (St. Louis, MO). TALON metal afﬁnity resin was
from Clontech (Mountain View, CA). Glutathione Sepharose 4B,
Superdex™ 200 HR 10/30 pre-packed column and HRP-conjugated
sheep anti-mouse and goat anti-rabbit IgGs were from GE Healthcare
(Pitscataway, NJ). Monoclonal anti-GST antibodies (Clone B-14) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Production
and characterization of speciﬁc rabbit polyclonal antibodies against the
a2 subunit isoform of the V-ATPase was previously described [1].
2.2. Synthetic peptides
Peptides were synthesized, puriﬁed by HPLC and analyzed
by mass spectrometry in the MGH Peptide/Protein Core Facility.
All a2N-derived peptides were synthesized with a biotin-tag on the
N-terminus for immobilization on streptavidin-agarose beads and
with an additional C-terminal cysteine residue for immobilization on
beads using sulfhydryl-speciﬁc crosslinkers. A peptide corresponding
to the PB-domain of ARNO was synthesized containing either a non-
phosphorylated or a phosphorylated Ser392 residue. Peptide stock
solutions were prepared in DMSO at 5 mM concentration and stored
at −20 °C.
2.3. DNA constructs, protein expression and puriﬁcation
Constructs corresponding to aminoacid residues 1–133 (a2N-N) and
134–393 (a2N-C) of the mouse V-ATPase a2-isoform were ampliﬁed
using Expand High Fidelity PCR System and subcloned into a pIVEX2.4d
vector (Roche, Indianapolis, IN) using NcoI/SmaI restriction sites. The
resulting constructs contain a modiﬁed N-terminal 6XHis-tag
(MSGSHHHHHHSSGIEGRGRLIKMT). Both constructs were in vitro
translated using the RTS100 kit (Roche, Indianapolis, IN) and used in
pull-down experiments. A construct corresponding to amino acid
residues 1–402 of mouse V-ATPase a2-isoform (a2N) was ampliﬁed
as above and subcloned into NdeI/NotI restriction sites of pET28b
vector (Novagen, Gibbstown, NJ) in frame with a thrombin cleavable
N-terminal 6XHis-tag. Recombinant a2Nproteinwas expressed in E. coli
BL21(DE3) cells and puriﬁed from inclusion bodies under denaturing
conditions (in the presence of 6 M Guanidine–HCL) on Talon beads
(Clontech) and refolded into 1 M NDSB-256, 100 mM CHES–NaOH, pH
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with iFOLD™ Protein Refolding System 2 (Novagen, Gibbstown, NJ).
After refolding, a2N protein was dialysed into 100 mMCHES–NaOH, pH
9.0, and 1 mMDTT immediately prior to immobilization on BIAcore chip.
Cytohesin-2 or ARNO is a highly conserved protein with 99.25%
identity between human and mouse species. There are only three
similar substitutions between human and mouse amino acids N86H,
A124S and E229D in ARNO sequences. Thus, in our experiments we
used human ARNO, since the crystal structure of its Sec7-domain in
complex with Arf1 has been previously solved and was used in our
modeling studies. The following constructs corresponding to wild-
type human ARNO (triglycine variant) and its domains were
generated: i) 1–400aa, full-length ARNO(wt); ii) 1–60aa, coiled-coil
(CC) domain; iii) 61–252aa, Sec7-domain; iv) 253-378aa, plekstrin-
homology (PH) domain; and v) 379–400aa, polybasic (PB) domain.
All domains of ARNOwere ampliﬁedwith simultaneous incorporation
of a 6XHis tag using Expand High Fidelity PCR System and subcloned
into pGEX6P-1 vector (GE Healthcare, Pitscataway, NJ) using EcoRI/
NotI restriction sites. The resulting constructs contain an N-terminal
GST-tag and a C-terminal 6XHis tag. All ﬁve recombinant proteins
were expressed in E. coli BL21(DE3) cells (Stratagene) and were
puriﬁed by sequential chromatography on TALON beads (Clontech)
and glutathione Sepharose 4B beads (GE Healthcare) according to the
manufacturer's instructions. Alternatively, GST-tagged ARNO(wt) was
puriﬁed by sequential chromatography on glutathione Sepharose 4B
beads (GE Healthcare) and Superdex™ 200 HR 10/30 pre-packed
column (GE Healthcare) using the “AKTA Puriﬁer” system (GE
Healthcare) according to the manufacturer's instructions. For BIAcore
experiments, the GST-tag was cleaved from the Sec7-domain by
PreScission Protease™ (GE Healthcare) according to the manufac-
turer's instructions.
2.4. Biotinylated peptide pull-down assay
All a2N-derived peptides were immobilized by an N-terminal
biotin-tag, which ensures the same efﬁciency and equivalent binding
to streptavidin-agarose beads. Simultaneous pull-down experiments
with immobilized peptides were performed using highly puriﬁed
recombinant GST-ARNO(wt) or GST-Sec7-6His as described below.
First, equal amounts (7 nmol) of the corresponding 22 synthetic
peptideswere immobilized on 25 µl of 50% streptavidin-agarose CL-4B
(Fluka) slurry by mixing them overnight at 4 °C in 500 µl of binding
buffer (10 mM HEPES pH 7.5, 1 mM EDTA, 1 mM DTT, 100 mM NaCl,
10% glycerol, 0.1% NP-40). To remove unbound peptides, beads were
collected by centrifugation and washed in 500 µl ice-cold binding
buffer. Next, equal amounts (20 pmol) of highly puriﬁed recombinant
GST-ARNO(wt) or GST-Sec7-6His were added to the beads containing
immobilized peptides and incubated for 2 h at 4 °C in 500 µl of binding
buffer. After washing beads four times in ice-cold binding buffer, the
interacting GST-ARNO/a2N-derived peptide complexes were eluted
by boiling in SDS-PAGE sample buffer for 10 min at 95 °C, resolved by
SDS-PAGE and analyzed by Western blotting using monoclonal anti-
GST antibody. In pull-downexperimentswith ARNO-derived peptides,
equal amounts (7 nmol) of biotin-tagged synthetic peptides were also
immobilized on streptavidin-agarose beads followed by incubation
with 10 µl of in vitro translated 6His-a2N(wt) recombinant protein.
Pull-down experiments and SDS-PAGE analysis were performed as
described above and interacting 6His-a2N/ARNO-derived peptide
complexes were analyzed by Western blotting using polyclonal anti-
a2N antibody. All experiments were repeated at least three times with
similar results.
2.5. GST fusion protein pull-down assay
In this assay, the direct interaction of recombinant proteins was
studied. The puriﬁed recombinant GST-ARNO(wt) and GST-taggedARNO domain constructs (100 pmol) were incubated with 10 µl of in
vitro translated 6His-a2N recombinant protein at 4 °C for 2 h in 500 µl
of binding buffer (10 mM HEPES, 1 mM EDTA, 1 mM DTT, 100 mM
NaCl, 10% glycerol, 0.1% NP-40) with gentle rotation. Then the
interacting recombinant proteins were immobilized on glutathione
beads by incubationwith 50 µl of 50% glutathione Sepharose 4B slurry
for 2 h at 4 °C. The beads were collected by centrifugation andwashed
5 times with 500 µl ice-cold binding buffer. Interacting proteins were
eluted by boiling in SDS-PAGE sample buffer for 10 min at 95 °C,
resolved by SDS-PAGE and analyzed by Western blotting using
polyclonal anti-a2N antibodies. Alternatively, pull-down experiments
with GST-ARNO(wt) and GST-only as control were performed using in
vitro translated and methionine-35S metabolically labeled recombi-
nant proteins a2N-N-[35S] and a2N-C-[35S], corresponding, respec-
tively, to N-terminal (a2N1–133) and C-terminal (a2N134–393) parts of
a2N. Pull-down experiments and analysis by autoradiography were
performed as previously described [1]. All experiments were repeated
at least three times.
2.6. Real-time binding and kinetic analysis by surface plasmon
resonance (SPR)
SPR binding assays were performed at 25 °C on a BIAcore™ T100
instrument (GE Healthcare). All reagents, including buffers, sensor
chips and the amine coupling kit, were obtained from GE Healthcare.
For kinetic analysis of the binding of ARNO(wt) with a2N(wt),
puriﬁed 6His-a2N (5 µg/ml) in 10 mM sodium acetate (pH 4.0) was
immobilized at 80 response units (RU) on a CM4 sensor chip using an
amine coupling kit according to the manufacturer's instructions. The
same kit was used to perform blank immobilization to create a
reference surface on the same chip. Samples of puriﬁed GST-ARNO
(wt) at concentrations ranging from 0.25 to 4 µM were injected for
6 min over active and reference surfaces at a ﬂow rate of 30 µl/min in
NBS-EP, 1 mM DTT running buffer (10 mM Hepes, pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.05% Surfactant P20, 1 mM DTT). For kinetic
analysis of the binding of the ARNO Sec7-domain with a2N-01
peptide, neutravidin (10 µg/ml) in 10 mM sodium acetate (pH 5.0)
was immobilized at about 1200 RU on two surfaces of a CM4 sensor
chip using an amine coupling kit. Following that, biotinylated a2N-01
peptide (50 RU) and amine-PEG3-biotin (25 RU) were irreversibly
captured by neutravidin to create active and a reference surfaces,
respectively. Puriﬁed Sec7-6His recombinant protein was injected for
3.5 min over active and reference surfaces at concentrations ranging
from 0.05 to 1 µM and a ﬂow rate of 100 µl/min in NBS-EP, 1 mM DTT
running buffer. Dissociation of the complexes was monitored for
10 min, and then the regeneration of the sensor surfaces was
performed using 0.05% SDS with 1-min injection in the running
buffer at a 20 µl/min ﬂow rate. BIAcore™ T100 Evaluation software
was used to calculate the association and dissociation rate constants
(kon and koff) with a 1:1 ﬁtting model. The dissociation constant (KD)
was determined from the kon/koff values. To estimate afﬁnity of
interaction the corresponding free energy of binding ΔGbind=RTlnKD
was calculated as previously described [35].
2.7. NMR data collection, processing and peptide structure calculation
The non-phosphorylated (ARNO375–400) and phosphorylated
(ARNO375–400p) peptides (2 mM ﬁnal concentration of each peptide)
of ARNO were prepared by dissolving an appropriate amount in
50 mM phosphate buffer, pH 6.8. The one dimensional (1D) and two
dimensional (2D) 1H NMR spectra including total correlation
spectroscopy (TOCSY) and nuclear Overhauser enhancement spec-
troscopy (NOESY) were obtained at a temperature of 288 K on an
Avance Bruker NMR spectrometer at 700 MHz proton frequency.
TOCSY and NOESY spectra of the peptide were recorded with mixing
times of 80 and 300 ms, respectively. All the NMR datawere processed
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Peak-picking and data analysis of the Fourier-transformed spectra
were performed with the SPARKY program [36]. Assignments were
carried out according to classical procedures including spin-system
identiﬁcation and sequential assignment [37]. The three-dimensional
structure of the peptides ARNO375–400 and ARNO375–400p were
calculated based on both distance and angle restraints by using the
CYANA 2.1 program package [38]. Dihedral angle restraints were
calculated from chemical shifts using torsion angle likelihood
obtained from shift and sequence similarity (TALOS) [37]. In total
twenty ARNO375–400 and twenty ARNO375–400p structures were
calculated.2.8. Bioinformatics analysis and ARNO homology modeling
The prediction of coiled-coil regions and the secondary structure of
a2N, used in the design and synthesis of peptides was carried out by
direct submission of the a2N amino acid sequence to the following
websites (http://www.ch.embnet.org/software/COILSform.html)
[39] and (http://bioinf.cs.ucl.ac.uk/psipred/psiform.html) [40,41].
The spatial structure of human ARNO was performed by homology
modeling using Modeller9v2 and Gromacs software [42].Fig. 1.Design and synthesis of a2N-derived peptides. a) Design of a2N-derived peptides accord
are shown as green cylinders,β-strands are shown as yellow arrows. b) Names, position, lengt
peptides are indicated in red and non-interacting peptides are in black.3. Results
3.1. Mapping the binding sites on the N-terminal cytosolic tail of the
V-ATPase a2-isoform (a2N) that are involved in interaction with ARNO
In order to map the a2N motifs that interact with ARNO, an
a2N-derived peptide pull-down approach was applied. Since the
three-dimensional structure of V-ATPase a-subunit isoforms is
currently unknown, the rational design of a2N-derived peptides was
performedusing a prediction of the secondary structure formouse a2N
using the PSIPRED server (http://bioinf.cs.ucl.ac.uk/psipred/psiform.
html) [40,41]. Moreover, the presence of coiled-coil domains was also
predicted on a2N using COILS software (http://www.ch.embnet.org/
software/COILS_form.html) [39]. According to this program, the
mouse V-ATPase a2-isoform CC-domain spans from L92 to Y128.
Using these two in silico prediction programs for guidance, 22 peptides
covering the 1–402 amino acids of a2N were designed (Fig. 1a) and
synthesized (Fig. 1b). Recently, the involvement of CC-motifs in
an interaction with syntaxin was demonstrated for the a1-isoform of
V-ATPase fromDrosophilamelanogaster [43]. Therefore, in order to test
its possible involvement in interaction with ARNO the longest peptide
a2N-06 (a2N92–127) corresponding to the predicted CC-domain of a2N
was synthesized.ing to their secondary structure predicted by PSIPRED and COILS software. Theα-helices
h and sequence of a2N-derived peptides. Bio— biotin-tag. Cys— cysteine. The interacting
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interaction of GST-ARNO(wt) with six of the a2N-derived peptides
(a2N-01, a2N-03, a2N-11, a2N-12, a2N-18 and a2N-22) (Fig. 2a). The
other 16 peptides, including a2N-06, which represents the putative
CC-domain of a2N, did not bind to GST-ARNO(wt). The speciﬁcity
of the GST-ARNO(wt) interaction was further conﬁrmed using a
GST-only construct as a control in the a2N-derived peptide pull-down
assay (Fig. 2b). In order to conﬁrm the involvement of multiple sites
on a2N in the interaction with ARNO, we also used a recombinant
protein pull-down assay. For this purpose a2N was divided into two
parts: i) a2N-N (or a2N1–133), the N-terminal part which contains
sequence covered by the peptides from a2N-01 to a2N-06; and
ii) a2N-C (or a2N134–393), the C-terminal part which contains se-
quence covered by the peptides from a2N-07 to a2N-22. In vitro
translated a2N-N and a2N-C mutants were used in pull-down
experiments with puriﬁed GST-ARNO(wt) and demonstrated that
both parts of a2N could interact with wild-type ARNO (Fig. S1). Thus,
our data indicate that while multiple interaction motifs of a2N are
involved in the interaction with ARNO, its predicted CC-domain does
not appear to be involved in this process.
3.2. Homology modeling of human ARNO and mapping the binding sites
on ARNO that are involved in interaction with a2N
Cytohesin family members including ARNO contain the following
distinct domains: i) CC-domain (CC, brown); ii) Sec7-domain (Sec7,Fig. 2. Interaction of a2N with ARNO is mediated by multiple sites. a) a2N-derived peptide p
beads and incubated with puriﬁed recombinant GST-ARNO(wt). Interacting complexes we
described in Materials and methods. The interacting peptides are indicated in red and n
interacting peptides incubated with either GST (negative control) or GST-ARNO(wt). The ﬁrs
(lane 2) are loaded onto the gel. The a2N-derived peptides were used in pull-down assay as
only.yellow); iii) PH-domain (PH, green) and iv) PB-domain (PB, blue) as
well as linkers: v) Sec7 and PH-linker domains (LK, magenta) and
vi) PH and PB-linker domains (white) (Fig. 3a) [33,44]. In order to
properly deﬁne boundaries between these domains and regulatory
elements, homology modeling of ARNO was performed. A spatial
structure of human ARNO without the N-terminal CC region was
made using the crystal structure of the autoinhibited form of Grp1
(also called ARNO3 or cytohesin-3) (PDB ID: 2R09) as a template
(Fig. 3b) [32]. For 3D-structure, see also Supplementary information,
Movie S1. In order to model full-length ARNO, the C-terminal domain
of the human EB1 protein (PDB ID: 2HKQ, chain A) was used as a
template for the CC-domain of ARNO. Some dihedral angles in the
chimeric template were manually edited in SWISS-PDB Viewer [45] to
avoid steric clashes. Energy minimization in Gromacs [46] was
performed for equilibration of the template. The ﬁnal models were
built with Modeller9v2 [42] (Fig. 3). For 3D-structure, see also
Supplementary information, Movie S2. Domains and structural
elements of ARNO are colored and their amino acid positions are
indicated as in Fig. 3a.
Toexamine the ability of thesewell-deﬁned and functionally distinct
domains of ARNO to interact with a2N,we cloned full-lengthARNO(wt)
and its four domains separately for bacterial expression of recombinant
proteins (Fig. 4a). The Sec7/PH-linker region (242–261aa) was divided
between the Sec7-domain and the PH-domain, while the PH/PB-linker
region (375–379aa) was cloned as a part of the PH-domain (Fig. 3a).
Interaction of a2N with full-length ARNO(wt) was used as a control inull-down assay. The indicated a2N-derived peptides were immobilized on streptavidin-
re eluted and analyzed by Western blotting using monoclonal anti-GST antibodies as
on-interacting peptides are in black. b) Pull-down assay with selected a2N-derived
t two lanes show the patterns obtained when either GST-only (lane 1) or GST-ARNO(wt)
described above and shown speciﬁc interaction with GST-ARNO(wt) but not with GST-
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used as baits in GST pull-down experiments with in vitro translated
recombinant a2N as a prey. Interacting proteins were detected by
western blot analysis with a2-speciﬁc antibodies as described in
Materials and methods. Our data demonstrated that a2N interacts
strongly with the ARNO Sec7-domain and weakly with its PH-domain,
while no interaction with either the CC-domain or the PB-domain ofFig. 4. Cytosolic tail of a2-subunit isoformofV-ATPase interacts stronglywith Sec7-domain
andweakly with PH-domain of ARNO. a) Purity of GST and 6His double-tagged ARNO(wt)
and its domains used in GST pull-down experiments. Proteins were resolved by Nu-PAGE
and stained by Ponceau-S. Molecular weight markers are shown on the right. b) The
amountofa2Npulled-downbyeach fusionproteinwasanalyzedbyWesternblottingusing
speciﬁc anti-a2N antibodies. Wild-type ARNO(wt) and its Sec7-domain showed strong
binding with a2N in this assay. Weak interaction of a2N with PH-domain could also be
detected. Molecular weight markers are shown on the right.ARNO could be detected (Fig. 4b). In order to determine whether the
Sec7/PH-linker region itself could interact with a2N, we synthesized a
peptide corresponding to the Sec7/PH-linker region (242–261aa) of
ARNO (Figs. 3a and 5a), and we reproducibly observed an interaction of
a2Nwith this linker region (Fig. 5b). Thus, ourproteinGSTpull-downand
peptide pull-down assays demonstrated that a2N strongly interactswith
ARNO's catalytic Sec7-domain, while weak binding to the PH-domain
and the linker between these two domains was also detected.Fig. 3. Homology modeling of the structure of the autoinhibited ARNO. a) Schematic
representation of domains and regulatory elements of ARNO. These structures are
indicated as follows: i) CC-domain (1–60aa) in brown; ii) Sec7-domain (61–242aa) in
yellow; iii) Sec-7-PH-linker (LK) (242–261aa) in magenta; iv) PH-domain (262–375aa)
in green; v) PB-domain (376–400aa) in blue. Boundaries of the domains are indicated
as amino acid numbers. b) Ribbon representations of a molecular model of delCC-ARNO
in its monomeric and autoinhibited state. The autoinhibited model of ARNO without its
CC-domain was performed based on the crystal structure of GRP1 (PDB ID: 2R09).
Details are described in Results. Structural domains and elements of delCC-ARNO are
indicated as in a. For 3D-structure see also Supplementary information, Movie S1. c)
Ribbon representation of a molecular model of full-length ARNO(wt) in its dimeric and
autoinhibited state. In order to model full-length ARNO(wt), the C-terminal domain of
human EB1 protein (PDB ID: 2HKQ, chain A) was used as a template for the CC-domain
of ARNO while the crystal structure of GRP1 (PDB ID: 2R09) was used as a template for
the Sec7/PH/PB-domains. Details are described in Results. Structural domains and
elements of delCC-ARNO are indicated as in a. For 3D-structure see also Supplementary
information, Movie S2.
Fig. 5. Phosphorylation-dependent interaction of a2N with PB-domain of ARNO. a) Names, position, length and sequence of synthetic ARNO-derived peptides are shown as follows:
i) Sec7-PH-linker; ii) non-phosphorylated PB-domain (ARNO375–400) and iii) phosphorylated PB-domain domain (ARNO375–400p). Serine392 (Ser392) of ARNO the substrate for
PKC-dependent phosphorylation is indicated in red. b) Peptide pull-down assay showing interaction of a2N with Sec7-PH-linker of ARNO. c) Phosphorylation-dependent
interaction of a2N with ARNO-derived peptide corresponding to the PB-domain of ARNO. Corresponding ARNO-derived peptides were immobilized on streptavidin-beads and
incubated with in vitro translated recombinant a2N. Interacting complexes were eluted and analyzed by Western blotting using anti-a2N antibodies.
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PB-domain of ARNO
Next we tested whether: i) interaction of a2N with the PB-domain
(379–400aa, short 22 amino acids construct) was prevented by the
addition of two tags (bulky 26 kDa GST-tag and His-tag) on the ARNO
construct (Fig. 4b) and ii) whether this interaction could be modiﬁed
by Ser392 phosphorylation of the PB-domain of ARNO. Thus, we
synthesized a biotinylated peptide called ARNO375–440 which covers
the PB-domain (379–440aa) and also includes four additional amino
acids of a PH/PB-linker (375–378aa) (Figs. 3a and 5a). Also a
phosphorylated version of this peptide ARNO375–440p (Ser392-residue
is known to be phosphorylated by PKC in vivo) was synthesized
(Fig. 5a) [34]. Using these peptides in pull-down experiments, a direct
interaction of a2N with non-phosphorylated ARNO375–400 was
demonstrated (Fig. 5c). Importantly, this interaction was speciﬁc
since interaction between a2N and ARNO375–400p it was completely
abolished by Ser392-phosphorylation (Fig. 5c).
3.4. Structural changes of the ARNO375–400 peptide caused by its
Ser392-phosphorylation
In order to understand the phosphorylation-dependent mecha-
nism of interaction between a2N and ARNO-derived peptides, the
structural traits of the non-phosphorylated (ARNO375–400) and
phosphorylated (ARNO375–400p) peptides were determined by solu-
tion NMR spectroscopy. All amino acids of the two peptides were
sequentially assigned. The connectivity diagrams of ARNO375–400 (see
Supplementary information, Fig. S2a–e) and ARNO375–400p (see
Supplementary information, Fig. S3a–e) respectively, are indicative
of a helical conformation with the sequential HN–HN, Ha–HN(i, i+3),
Ha–HN(i, i+4), and Ha–Hb(i, i+3) connectivities. Data from
assigned 2D NOESY spectra and primary amino acid sequence were
used as input for the automated structure calculation using the Cyana
2.1 package [38]. In total, an ensemble of twenty calculated structuresresulted in an overall mean root square deviation (RMSD) of 0.69 Å for
non-phosphorylated ARNO375–400 (Fig. 6a) (PDB ID: 2kpa and BMRB
ID: 16550) and 0.378 Å for ARNO375–400p (Fig. 6b) (PDB ID: 2kpb and
BMRB ID:16551). For 3D-structures seealso Supplementary information
Movie S3 and Movie S4. All these structures have energies lower than
−100 kcal mol−1, no NOE violations greater than 0.3 Å and no dihedral
violations greater than 5°. Summary of the statistics for twenty
structures are shown in the table (see Supplementary information,
Fig. S5). The calculated structureARNO375–400 forms a stableN-terminus
regionwith a helix extending from 378 to 384, followed by a short loop
from 385 to 387, a second helix between 388 and 391 and a third very
unstable 310 helix from 394 to 397 (Fig. 6a). The remaining C-terminal
amino acids form a ﬂexible structure. Structural regions of ARNO375–400
are also reﬂected in the NOE plot (see Supplementary information,
Fig. S2). Electrostatic potential surface analysis showed that the peptide
is strongly basic in nature, reﬂecting its name, thepolybasic (PB)domain
of ARNO (Supplementary information, Fig. S4) [34]. By comparison
the structural assignment and calculation of ARNO375–400p, showed an
N-terminus α-helix extending from residues 377–384 and a second
α-helix at the C-terminus composed of residues 390–396, forming
together a stable helix–loop–helix structure with a RMSD value of
0.378 Å (Fig. 6b) (see Supplementary information, Fig. S3). The
loop between the two α-helices extends from residues 385–389.
Superimposition of both structures, ARNO375–400 and ARNO375–400p
(Fig. 6c) via N-terminus 1–10 residues revealed a nice ﬁtting in this
regionwitha rootmeansquaredeviationof 0.68 Åbutwithdifference in
the C-terminus. An alignment of the structures at the N-termini
resulted in adistancedeviationof 105°between the twoC-termini at the
loop region of ARNO375–400 and ARNO375–400p, respectively. Thus, the
Ser392-phosphorylation of ARNO375–400 peptide produced signiﬁcant
structural changes in the C-terminus, resulting in the disruption of the
α-helix at the Ser392 residue in the non-phosphorylated ARNO375–400. In
contrast, ARNO375–400p displayed an extended helix through Ser392 and
attained amaximum stable structure (Fig. 6c). These structural changes
could be responsible for the inhibitory effect of Ser392-phosphorylation
Fig. 6. Phosphorylation-dependent conformational changes of ARNO375–400 and
ARNO375–400p peptides. a) Ribbon representation for the NMR structure of the peptide
ARNO375–400 (PDB ID: 2kpa and BMRB ID: 16550) corresponding to non-phosphorylated
PB-domain of ARNO. Superimposition of the ten lowest energy structures of the peptide
ARNO375–400 is shown inyellow. For3D-structure see Supplementary information,MovieS3.
b) Ribbon representation for the NMR structure of the peptide ARNO375–400p (PDB ID: 2kpb
and BMRB ID: 16551) corresponding to phosphorylated PB-domain of ARNO. Superimpo-
sition of the ten lowest energy structures of the peptide ARNO375–400p is shown in green.
For 3D-structure see Supplementary information, Movie S4. c) Superimposition of the
average structure ARNO375–400 (yellow) and ARNO375–400p (green) showing the differ-
ent angle between the helices in both structures due to phosphorylation of the Ser392 of the
PB-domain of ARNO. For assignment of cross-peaks in the NOESY spectrum of ARNO375–400
and ARNO375-400p peptides see Supplementary information, Figs. S1 and S2. For assignment
3D NMR of ARNO375–400 and ARNO375-400p peptides see Supplementary information,
Figs. S3A and S3B. For statistics of NMR data of ARNO375–400 and ARNO375–400p peptides see
Supplementary information, Fig. S4.
Fig. 7. Homology modeling of activated ARNO and conformational changes caused by
phosphorylation of Ser392 in its PB-domain. a) Ribbon representation of a molecular
model of non-phosphorylated ARNO in its activated state in a complex with Arf6.
Modeling was performed by superimposition of the known structure of the Sec7-
domain of ARNO in a complexwith Arf1 (PDB ID: 1S9D) onto a delCC-ARNO/Arf6model
as described in Results. The PH-domain was shadowed to indicate its arbitrary position.
Structure of non-phosphorylated peptide ARNO375–400 (see Fig. 6a) was used as a
template of non-phosphorylated PB-domain (in blue). Position of Ser392 on the ARNO
PB-domain is shown in red. Molecular model of Arf6 is shown in cyan, while other
domains and structural elements of ARNO are colored as in Fig. 3a. Ten helices of the
Sec7-domain are numbered and indicated correspondingly from αA to αJ as previously
described [32,51]. For 3D-structure see Supplementary information,Movie S5. b) Ribbon
representation of a molecular model of phosphorylated ARNO in its activated state in a
complexwith Arf6.Modelingwas performed by superimposition of the known structure
of the Sec7-domain of ARNO in a complexwith Arf1 (PDB ID: 1S9D) onto a delCC-ARNO/
Arf6 model as described in Results. The PH-domain was shadowed to indicate its
arbitrary position. Structure of phosphorylated peptide ARNO375–400p (see Fig. 6b) was
used as a template of phosphorylated PB-domain (in blue). Phosphorylated Ser392
residue is shown in red. Molecular model of Arf6 is shown in cyan, while other domains
and structural elements of ARNO are colored as in Fig. 3a. Ten helices of the Sec7-domain
are indicated correspondingly from αA to αJ as previously described [32,51]. For 3D-
structure see Supplementary information, Movie S6.
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experiments (Fig. 5c) as discussed below.
3.5. Homology modeling of ARNO conformational changes caused by
Ser392-phosphorylation of its PB-domain
A spatial structure of human ARNO without the N-terminal CC
region was derived using homology modeling as described above. The
crystal structure of the autoinhibited form of Grp1 (PDB ID: 2R09) was
also used as a template and the model was built using Modeller9v2
software [42]. A spatial model of activated ARNO is shown in a
complex with Arf6 and the structure was equilibrated in Gromacs
(Figs. 7a,b) [46]. Nucleotide exchange on both Arf6 and Arf1 is
activated by the Sec7-domain of ARNO. Superimposition of the known
crystal structure of the human Sec7–Arf1 complex onto ARNO with
Arf6 shows that the PH-domain and Arf6 occupy the same space
(Fig. S6). Thus, Arf6 binding may take place only concurrently with
conformational changes in ARNO. First, since the exact relative
positions between the Sec7 and PH-domains in activated cytohesinsis currently unknown, during this step the PH-domain in the ARNO
model was manually moved to a position that allows binding of
Arf6 (Figs. 7a,b). To indicate its arbitrary position in this model, the
PH-domain has been shadowed (Figs. 7a,b). During the second step,
the NMR structure of non-phosphorylated peptide ARNO375–400
(Fig. 6a) (PDB ID: 2kpa and BMRB ID:16550) was used for modeling
of the non-phosphorylated PB-domain in the ARNO model (Fig. 7a).
For 3D-structures, see also Supplementary information, Movie S5. On
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ARNO375–400p (Fig. 6b) (PDB ID: 2kpb and BMRB ID: 16551) was used
for modeling of the phosphorylated PB-domain in the ARNO model
(Fig. 7b). For 3D-structures, see also Supplementary information,
Movie S6. Thesemodeling studies revealed the existence of a potential
interaction pocket that is formed by the αC, αE and αG helices of the
Sec7-domain and two semi-helices of the PB-domain of activated
ARNO (Fig. 7a). This model also predicted that conformational
changes caused by Ser392-phosphorylation could result in the opening
of this interaction pocket and, thus, modifies its binding interfaces on
both Sec7 and PB-domains of ARNO (Fig. 7b). Therefore, we next
performed experiments designed to identify the speciﬁc part of the
a2N that may potentially be involved in the binding within this
interaction pocket.Fig. 8. Identiﬁcation of interaction motif of a2N that is involved in speciﬁc binding with the S
peptides a2N-01 and a2N-03 in pull-down experiments. The peptide pull-down assay was p
and incubated with puriﬁed recombinant GST-only or GST-Sec7-domain. Interacting complex
as described in Materials and methods. The loading controls for GST-only (lane 1) or GST-Se
domain (b) or PB-domain (c) of ARNO. The peptide pull-down assay was performed with
puriﬁed recombinant GST-PH-domain (b) or GST-PB-domain (c). Interacting complexes w
described in Materials and methods. The loading control of GST-PH-domain (b) or GST-PB-3.6. Identiﬁcation of a motif on a2N that is involved in speciﬁc binding
with the Sec7-domain of ARNO
In order to map the motif(s) on a2N that interact with the Sec7-
domain of ARNO, the peptide pull-down approach was also applied
using six of the a2N-derived ARNO-interacting peptides (a2N-01,
a2N-03, a2N-11, a2N-12, a2N-18 and a2N-22). The peptides were
immobilized on streptavidin-beads and incubated with puriﬁed
recombinant GST-only or GST-Sec7-domain. These experiments
demonstrated that only two peptides a2N-01 and a2N-03 interact
with the catalytic Sec7-domain of ARNO (Fig. 8a). Next, we tested the
speciﬁcity of binding of these two peptides to Sec7 in comparison to
other domains of ARNO. These pull-down experiments demonstrated
that peptide a2N-01 (a2N1–17, MGSLFRSESMCLAQLFL) showedec7-domain of ARNO. a) Catalytic Sec7-domain of ARNO interacts with two a2N-derived
erformed with six a2N-derived interaction peptides immobilized on streptavidin-beads
es were eluted and analyzed byWestern blotting usingmonoclonal anti-GST antibodies
c7 (lane 2) are shown. b,c) Peptide a2N-01 speciﬁcally interacts with Sec7 but not PH-
peptides a2N-01 and a2N-03 immobilized on streptavidin-beads and incubated with
ere eluted and analyzed by Western blotting using monoclonal anti-GST antibodies as
domain (c) is shown on the left.
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PH-domain (Fig. 8b) or with the PB-domain (Fig. 8c) of ARNO. On the
other hand, peptide a2N-03 lacks this speciﬁcity and interacts equally
well with both the PH-domain (Fig. 8b) and PB-domain (Fig. 8c) of
ARNO.
3.7. Estimation of the binding afﬁnities using surface plasmon resonance
analysis
Todetermine thedissociation constants (KD) for bindingof a2N(wt)/
ARNO(wt) proteins and for the speciﬁc peptide a2N-01/Sec7-domain
interaction, a kinetic analysis was performed using the BIAcore™ T100
system as described in Materials andmethods. Speciﬁc concentration-
dependent responses were obtained for both interactions (Fig. 9).
When various concentrations of His6-ARNO(wt) were applied toFig. 9. Estimation of the binding afﬁnities for the speciﬁc interaction domains between
V-ATPase a2-subunit isoform and ARNO. a) Kinetic analysis and estimation of a
dissociation constant (KD) for interaction between full-length a2N(wt) and ARNO(wt)
proteins. Sensorgrams for the binding of recombinant a2N-His6 immobilized as ligand
on the sensor chip, with various concentrations of His6-ARNO as analyte are shown. The
responses on the sensorgram are designated in resonance units (RU). The best ﬁtted
curveswith bivalent analyte interaction isothermwere obtained and the KD=3.13×10−7 M
value was determined using BIAcoreTM T100 evaluation software. b) Kinetic analysis and
estimation of KD for interaction between a2N-01 peptide and Sec7-domain of ARNO.
Sensorgrams for thebindingof a2N-01peptide immobilizedas ligandon the sensor chip,with
various concentrations of Sec7-domain as analyte are shown. The responses on the
sensorgram are designated in resonance units (RU). The best ﬁtted curves with single 1:1
interaction isothermwere obtained and the KD=3.44×10−7 M valuewas determined using
BIAcore™ T100 evaluation software.a2N-His6(wt) immobilized on a sensor chip, a speciﬁc real-time
bindingbetween the twoproteinswasobserved (Fig. 9a). The bestﬁtted
curves with bivalent analyte interaction isotherms were obtained and
calculation of KD was performed using the BIAcore™ T100 Evaluation
software. An association rate constant (kon) of 4.77×103 M−1 S−1 was
obtained and a dissociation rate constant (koff) of 14.95×10−4 S−1 was
determined, giving a dissociation constant of KD (koff/kon) for this
interaction ofKD=3.13×10−7 M. The kinetic analysis and estimation of
KD for the a2N-01/Sec-7 interaction was also calculated using a2N-01
peptide immobilized as ligand on the sensor chip, with various
concentrations of Sec7-domain as analytes (Fig. 9b). The best ﬁtted
curve was a single 1:1 interaction isotherm and kon was determined as
2.5×103 M−1 S−1 and koff was determined as 8.6×10−4 S−1 with a
calculated KD for this interaction of 3.44×10−7 M. For both interactions,
association rates were fast and dissociation rates were slow, which
resulted in the formation of a relatively stable complex that was readily
detectable in our pull-down (Figs. 2a,b and 8a) and previous
immunoprecipitation experiments [1]. Calculated free energies for
a2N(wt)/ARNO(wt) and a2N-01/Sec7 binding are −8.86 kcal mol−1
and−8.81 kcal mol−1, respectively [35]. These equivalent free energies
strongly indicate that speciﬁc binding between peptide a2N-01 in the
a2N and the Sec7-domain of ARNO is most likely one of the major
contributors to the high-afﬁnity interaction between a2N and ARNO.
4. Discussion
We previously showed that the V-ATPase functions as an
endosomal pH-sensor that recruits Arf6 and ARNO to the endosomal
membrane and provides a regulatory link between intra-endosomal
acidiﬁcation and protein trafﬁcking in the endosomal/lysosomal
protein degradative pathway [1,2]. While the a2-subunit isoform of
the V-ATPase is targeted to early endosomes and directly interacts
with ARNO in an acidiﬁcation-dependent manner, Arf6 speciﬁcally
interacts with the c-subunit of the V-ATPase. However, the molecular
mechanism(s) underlying these novel interactions of the V-ATPase
and their precise effects on downstream signaling pathways remain
obscure. In this study, we set out to identify the cognate binding
motifs on the a2-subunit isoform of V-ATPase and ARNO in order to
begin to understand how their interaction might be modulated.
First, wemapped the entire a2N in order to uncover themotifs that
are involved in binding with wild-type ARNO. Recombinant protein
pull-down assays with a2N-N (corresponding to the N-terminal part
of a2N1–133) and with a2N-C (corresponding to the C-terminal part of
a2N134–393) suggested the involvement of multiple sites that par-
ticipate in the a2N/ARNO interaction. The peptide pull-down
experiments also revealed the interaction of ARNO(wt) with six
(a2N-01, a2N-03, a2N-11, a2N-12, a2N-18 and a2N-22) out of the
twenty two a2N-derived peptides. Taken together, these data
demonstrate that both N-terminal and C-terminal parts of the a2N
are competent for binding with ARNO and multiple binding sites
located on both portions of the a2N are involved in the interaction
with ARNO.
Next, using the recently published crystal structure of GRP1 or
cytohesin-3 as a template [32], we applied a homology modeling
approach and generated the following 3D-structures for ARNO: i) the
dimeric form of full-length ARNO(wt) and ii) the monomeric form of
delCC-ARNO without its CC-domain. While the CC-domain of ARNO is
involved in binding to the CASP protein [47] our present and previous
[1] data indicated that it does not interact with a2N. It is, however,
generally accepted that the CC-domain of ARNO is involved in its
homo-dimerization [44] and it may have a regulatory role in binding
of ARNO with a2N. Indeed, our previous data demonstrated that
removal of the CC-domain from ARNO increased the interaction of
delCC-ARNO with the a2N [1]. Importantly, we demonstrated that
peptide a2N-06 corresponding to a putative CC-domain of the a2N
does not interact with ARNO. Thus, binding of ARNO with a2N is not a
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but rather is a complex and dynamic process involving multiple
interaction sites on both a2N and ARNO.
Our study revealed that the V-ATPase a2-subunit isoform interacts
with the following domains and structural elements of ARNO:
i) catalytic Sec7-domain; ii) lipid-binding plekstrin-homology (PH)
domain; iii) linker element between these domains (Sec7-PH-linker)
and iv) polybasic (PB) domain. The interaction of a2N with the Sec7-
domain of ARNO in pull-down experiments is quite strong and is
comparable to the interaction of a2N with full-length ARNO. In order
to identify the motif of a2N that is involved in speciﬁc binding with
the ARNO Sec7-domain, some additional pull-down experiments with
a2N-derived interacting peptides and the Sec7-domain of ARNO
were performed. We demonstrated that only two of the six identiﬁed
a2N-derived interacting peptides a2N-01 and a2N-03 could interact
with the Sec7-domain of ARNO. However, and importantly, only the
a2N-01 (a2N1–17, MGSLFRSESMCLAQLFL) peptide showed speciﬁcity
towards the Sec7-domain.
It is known that some synthetic peptides in solution may exert
strong but non-speciﬁc interactions. However, in context of the whole
intact protein, the motifs formed by these peptides may be shielded
and never be available for such potential interactions. This situation
may lead to an over-estimation of binding capacity and false-positive
results in experiments with synthetic peptides in solution. Indeed, we
suggest that this is the case with peptide a2N-03, since it interacts
equally strongly and not speciﬁcally with wild-type ARNO and its
Sec7-, PH- and PB-domains only in solution (Figs. 2 and 8). However,
the whole intact a2N reveals a predominant speciﬁcity towards the
ARNO Sec7-domain (Fig. 4). Thus, we hypothesize that in the context
of the properly folded a2-subunit isoform, the motif formed by
peptide a2N-03 is probably completely shielded by other parts of the
protein, which prevents its interaction with ARNO. We anticipate that
future structural studies on the a2N-subunit isoform will reveal the
exact location of this a2N-03 motif within the full-length protein.
It is also possible that some synthetic peptides in solution may not
necessary acquire the same conformation as their counterparts in the
intact protein. Thus, they may not precisely reﬂect the afﬁnity of
interactions with their binding partners that would occur in the
micro-environment of the whole protein. This situation would
produce an underestimation of binding capacity or even false-
negative results in binding experiments with synthetic peptides.
Therefore, the qualitative peptide binding assays need to be
conﬁrmed by quantitative methods such as the BIAcore assay using
both synthetic peptides and recombinant proteins. In the present
study, surface plasmon resonance studies conﬁrmed results from our
pull-down experiments by showing speciﬁc, high-afﬁnity, real-time
binding kinetics of the a2N-01 peptide with ARNO's Sec7-domain.
These data strongly suggest that these motifs are most likely to form
the predominant interaction site between these two proteins.
Additional evidence for an important role of the ARNO Sec7-domain
in the V-ATPase interaction comes from a recent study showing a
direct involvement of the Sec7-domain of the Gea2p protein (another
Arf-GEF) in interaction with Drs2p (a P-type ATPase) in yeast [48].
While a2N strongly interacts with the Sec7-domain, it binds only
weakly to the PH-domain of ARNO. A recent study revealed that a
stretch of twenty amino acids between the Sec7 and PH-domains,
called the Sec7-PH-linker (242–261aa), is an important regulatory
element in auto-regulation and activation of the GEF activity of ARNO
[32]. Using a synthesized Sec7-PH-linker in peptide pull-down
experiments we were able to demonstrate a direct interaction of
a2N with this important regulatory element of ARNO. Thus, the
relatively weak binding of the PH-domain with a2N could be
attributed to the requirement of the Sec7-PH-linker for full interaction
with the PH-domain. In addition, the PB-domain of the cytohesin-
family has also been identiﬁed as a crucial regulatory element in auto-
regulation and modulation of their Arf-GEF activity [32]. Here, wefound that a2N also speciﬁcally interacts with the ARNO375–400
peptide corresponding to the PB-domain of ARNO. Importantly,
this interaction was completely abolished by phosphorylation of
serine392 (Ser392) in the ARNO375–400p peptide. Here, for theﬁrst time,
the three-dimensional structures of both non-phosphorylated
(ARNO375–400) and phosphorylated (ARNO375–400p) peptides were
resolved by NMR. Homology modeling studies predicted dramatic
conformational changes in the ARNO interaction pocket caused by
Ser392-phosphorylation. Although these peptides make up only a
segment of ARNO, these conformational changes of the PB-domain
maymodulate the access and interaction of a2Nwith the Sec7-domain
of ARNO.
Importantly, it is well known that PKC-dependent phosphorylation of
Ser392 regulates the catalytic activity of ARNO. However, the molecular
mechanism of this regulation remained undetermined [34]. Thus, the
conformational changes of ARNO375–400 and ARNO375–400p peptides
reported in our study could also explain the mechanism of regulation of
the catalytic activity of ARNO by PKC-dependent Ser392-phosphorylation
[32,34]. In a recent study dealing with auto-regulation of the cytohesin
protein family, very similar non-phosphorylated and phosphorylated
synthetic peptides corresponding to the PB-domain of cytohesin-1 were
covalently ligated to the cytohesin-1 (residues 53–377) recombinant
protein [32]. These synthetic peptide/recombinantprotein chimeraswere
functionally active, andwhile the phosphorylation of this peptide leads to
activation of GEF activity of cytohesin-1, its dephosphorylation reverses
this activation. Thus, this studyalso supports thevalidity andphysiological
relevance of our structural studies with similar peptides such as
ARNO375–400 and ARNO375–400p as well as indicating the proper folding
of these synthetic peptides in solution.
Recently, the dissociation constants for interactions between various
subunits of the V-ATPase complex have been determined similarly
using the BIAcore™ assay. For the subunits NtpI (homolog of
mammalian a-subunit) and NtpF (homolog of mammalian G-subunit)
of the V-ATPase from Enterococcus hirae the dissociation constant was
KD=1.9×10−5 M, while for NtpF in complex with NptE (homolog of
mammalian E-subunit) the KD=1.5×10−7 M [49]. While the dissoci-
ation constant of the binding between Vph1p (homolog of mammalian
a-subunit) and VMA6 (homolog of mammalian d-subunit) was
KD=6.0×10−8 M, a KD of 2.7×10−7 M was determined for binding
of VMA6 with VMA1 (homolog of mammalian A-subunit) in the yeast
V-ATPase [50]. Thus, the afﬁnity of interactions between a2N(wt)/
ARNO(wt) and a2N-01/Sec7 that we ﬁnd here are in the same range as
those determined for interactions between subunits within V-ATPase
complex itself, indicating an important cell biological role of the
interaction between V-ATPase and small GTPase regulatory proteins.
In conclusion, we have found two structural elements that
are involved in speciﬁc and high-afﬁnity association of the V-ATPase
a2-subunit isoform and ARNO: i) an N-terminal binding motif formed
by the ﬁrst seventeen amino acids of the a2N (MGSLFRSESMCLAQLFL)
and ii) an interaction pocket formed by the catalytic Sec7 and
regulatory PB-domains of ARNO. Our data also suggest that the
transmembrane a2-subunit isoform of the V-ATPase may not simply
recruit and scaffold small GTPases to their target membrane during
its function as a pH-sensor [1]. Via its interaction with the catalytic
Sec7-domain and with the regulatory elements of ARNO, it could also
have a novel role as a modulator of Arf-GEF activity and ultimately as
modulator of activity of Arf-family small GTPases. Such a suggested
novel function of the V-ATPase as an Arf-GEF regulator remains to be
tested in future studies.
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